BioSpace News Archive

Once fully completed, the Mission Road facility will triple the production capacity in Duncan and increase operational efficiency.

ProTom International Holding Corporation (“ProTom”), a market-leading proton therapy technology manufacturer, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its Radiance 330 proton therapy system installed at Massachusetts General Hospital (“MGH”) in Boston, Massachusetts.

Doctors suggest that the “adaptive” motion of nickel-titanium rotary files used for root canal procedures decreases the instrument’s torque generation, thereby reducing the risk of tooth damage and file fracture

Recombinetics today announced a collaborative research project with Mayo Clinic to advance Osteogenesis Imperfecta (OI) research by developing the first-ever swine models of OI.

Beacon Communications, a Colorado-based leader of security and communications solutions, expands its market reach to eastern South Dakota and Northwest Iowa.

Nearly nine out of 10 migraine sufferers say they’ve missed important life events and special moments with friends and family due to a migraine, making fear of missing out an everyday reality for the more than 39 million migraine sufferers in the United States1.

The Imaging Wire announced that nominations are open for the first annual Imaging Wire Awards, honoring 2019’s most outstanding contributors to radiology practice and outcomes.

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic dermatitis.

Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of reagents and instruments for life science and clinical research, has been validating a growing number of immunohistochemistry (IHC) antibodies using the Advanced Cell Diagnostics™-branded RNAscope in situ hybridization (ISH) platform to leverage its transcriptomics approach to providing high quality, validated IHC antibodies to researchers.

Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, will provide a corporate update at the upcoming Jefferies Gene Therapy Summit in New York City on Tuesday, October 8, 2019 at 9:45 a.m. ET.